Clinical trials with Azacitidine

  • CT-EU-00041546

    Assessment of the effect of tamibarotene on patients with myelodysplastic syndrome

    This is a study on a new treatment for a type of blood disorder called high-risk myelodysplastic syndrome (HR-MDS). This condition often occurs when certain genes, like RARA, are overactive. First, a blood test will be done to see if participants have RARA. Participants will be given a new medicine named Tamibarotene along with another drug called Azacitidine. Results will be compared to those people who got a placebo pill (a pill without medicine) with Azacitidine. The main goal is to see if Tamibarotene with Azacitidine gets better results compared to the placebo with Azacitidine.

    • Tamibarotene
    • Azacitidine
  • Testing venetoclax for kids with relapsed leukemia

    This health study is focused on children with a certain type of leukemia, which is a type of blood cancer, that has unfortunately returned after initial treatment. The trial is examining a new cancer medicine called venetoclax in combination with other standard cancer treatment drugs to see if it can help these children. Some children will receive the standard treatment and some will also get the additional new drug. The study will see if kids who get the new treatment have better outcomes. Venetoclax has been designed to block a protein called BCL-2 that some cancer cells produce to avoid being killed by the body’s natural defenses. By blocking this protein, the hope is that the cancer cells can be destroyed.

    • Gemtuzumab Ozogamicin
    • Cytarabine
    • Fludarabine
    • Azacitidine
    • Venetoclax
  • Testing the effectiveness of oral azacitidine in treating Myelodysplasia Syndromes

    This is a medical research study about a disease of the blood and bone marrow, called low or intermediate-risk myelodysplastic syndrome. It involves a medicine known as oral azacitidine. In this study, some patients will receive the oral azacitidine plus supportive care (like medicines to control symptoms, blood transfusions, etc.), while others will get a placebo (a substance with no medical effect) plus supportive care. Researchers will look at how each patient is responding to better understand if the medicine is helping and if it’s safe.

    • Azacitidine
  • The impact of elenestinib on advanced systemic mastocytosis disorders

    This medical trial, known as AZURE, focuses on understanding the role of a drug called elenestinib (BLU-263) in helping patients with Advanced Systemic Mastocytosis (AdvSM) and associated conditions. AdvSM is a rare type of blood disorder that arises due to abnormal growth and accumulation of a type of white blood cell called mast cells. The study aims to identify the most suitable dose, evaluate the safety, and measure the effectiveness of elenestinib when used alone or in combination with another drug named azacitidine. The trial involves about four years of commitment per patient, including two years of active treatment followed by another two years of post-treatment follow-up. During this period, we will have monthly visits for the initial six months, and then we will follow up with the patients quarterly.

    • Elenestinib/BLU-263
    • Azacitidine
  • Treatment of patients with acute myeloid leukemia using ivosidenib in combination with azacitidine

    This is a phase 3b medical study that will examine the effects of combining Ivosidenib and Azacitidine in adults who’ve been newly diagnosed with a type of blood cancer known as Acute Myeloid Leukemia (AML) with a gene mutation called IDH1. The study is designed specifically for patients who are not eligible for intensive induction chemotherapy. The research is open-label, meaning everyone knows which drug is being used — there’s no placebo or hidden drug. In this important study, key clinical data will be made available to qualified scientific and medical researchers.

    • Ivosidenib
    • Azacitidine